Holen Sie sich die Stockscreener-App
1.23
2.38%
-0.03
Schlusskurs vom Vortag:
$1.26
Offen:
$1.29
24-Stunden-Volumen:
4.07M
Relative Volume:
0.56
Marktkapitalisierung:
$416.38M
Einnahmen:
$4.47M
Nettoeinkommen (Verlust:
$-71.67M
KGV:
-5.3063
EPS:
-0.2318
Netto-Cashflow:
$-59.58M
1W Leistung:
+1.65%
1M Leistung:
-19.61%
6M Leistung:
-15.17%
1J Leistung:
+19.42%
1-Tages-Spanne:
$1.23
$1.2986
1-Wochen-Bereich:
$1.17
$1.315
52-Wochen-Spanne:
$0.931
$2.725
Ocugen Inc Stock (OCGN) Company Profile
Firmenname
Ocugen Inc
Sektor
Branche
Telefon
484-328-4701
Adresse
11 GREAT VALLEY PARKWAY, MALVERN, PA
Compare OCGN vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCGN
Ocugen Inc
|
1.23 | 426.54M | 4.47M | -71.67M | -59.58M | -0.2318 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Canaccord Genuity | Buy |
| 2026-03-11 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-15 | Eingeleitet | Maxim Group | Buy |
| 2023-03-01 | Hochstufung | Chardan Capital Markets | Neutral → Buy |
| 2022-08-23 | Eingeleitet | Mizuho | Buy |
| 2022-06-15 | Fortgesetzt | ROTH Capital | Buy |
| 2022-06-02 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-07-26 | Eingeleitet | Noble Capital Markets | Outperform |
| 2021-06-11 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-09 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2021-02-04 | Hochstufung | H.C. Wainwright | Neutral → Buy |
Alle ansehen
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Inc (OCGN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
OCGN|Ocugen Inc|Price:1.262|Chg%:+0.051 - TradingKey
Ocugen Inc (OCGN) Valuation: PE, PB & Fair Value Analysis - TradingKey
Ocugen Inc (OCGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Ocugen Inc (OCGN) Balance Sheet - TradingKey
Ocugen Inc (OCGN) Cash Flow - TradingKey
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Inc (OCGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Ocugen Inc (OCGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Ocugen Inc (OCGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Has Ocugen's Recent Convertible Notes Offering Stabilized Its Financial Future - Kavout | AI
Ocugen Inc (OCGN) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
OCGN|Ocugen Inc|Price:1.210|Chg%:-0.060 - TradingKey
Ocugen Inc (OCGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Ocugen Inc (OCGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Ocugen Inc (OCGN) Institutional Confidence - TradingKey
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen, Inc. targets next generation brain gene therapies with new delivery approaches - Traders Union
OCGN Q2'26 Earnings: revenue estimate is 976.14K USD - TradingView
Ocugen (OCGN) Short Interest & Short Float | Updated Jul 2026 - MarketBeat
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Why Did OCGN Stock Rise Today? - Stocktwits
OCGN stock holds attention as Ocugen updates its pipeline - AD HOC NEWS
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen (OCGN) targets 250M-share authorization increase tied to $130M converts - Stock Titan
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen (OCGN) Proxy filing Summary - Quartr
Ocugen Targets $259 Million in MENA Licensing Deal for OCU400 - MyChesCo
OCGN Stock Rallies On Wall Street Optimism For Clinical Pipeline: Retail Awaits New Data - Stocktwits
Ocugen Inc. stock rises Tuesday, outperforms market - MarketWatch
Ocugen licenses gene therapy to Roots Pharmaceutica - BioXconomy
symbol__ Stock Quote Price and Forecast - CNN
Why Is Ocugen (NASDAQ:OCGN) Back on the Penny Stock Radar? - Kalkine Media
Ocugen Signs $255M MENA Licensing Deal for OCU400 Gene Therapy to Treat Retinitis Pigmentosa - Minichart
Ocugen signs OCU400 MENA license agreement - grafa.com
Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa - Ocugen, Inc.
Ocugen (OCGN) Secures Licensing Agreement for OCU400 in MENA Reg - GuruFocus
Ocugen Signs Term Sheet to License Retinitis Pigmentosa Gene Therapy to Roots Pharmaceutical, Al-Dhow in MENA Region - Moomoo
Ocugen (NASDAQ: OCGN) lines up OCU400 MENA license with $4M fees and 22% royalty - Stock Titan
Ocugen signs term sheet for OCU400 gene therapy in MENA region By Investing.com - Investing.com South Africa
Ocugen signs term sheet for OCU400 gene therapy in MENA region - Investing.com Nigeria
Ocugen Announces Binding Term Sheet for OCU400 License Deal in MENA Region with Roots Pharmaceutical - Quiver Quantitative
Gene therapy for inherited blindness set for MENA launch under Ocugen–Roots pact - Stock Titan
Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances - Yahoo Finance
Ocugen at Piper Sandler ophthalmology day: gene therapy push advances By Investing.com - Investing.com Canada
Ocugen at Piper Sandler ophthalmology day: gene therapy push advances - Investing.com
Ocugen’s Triple-Threat Pipeline: A $130M Cash Injection and a Summer of Make-or-Break Data - ad-hoc-news.de
Ocugen stock stays tied to pipeline progress. Nasdaq listing keeps the US angle clear. - Ad-hoc-news.de
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Finanzdaten der Ocugen Inc-Aktie (OCGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ocugen Inc-Aktie (OCGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Zhang Junge | Director |
Apr 01 '26 |
Option Exercise |
0.79 |
194,134 |
154,303 |
1,359,316 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):